Skip to main content
Top
Published in: Environmental Health and Preventive Medicine 1/2017

Open Access 01-12-2017 | Regular Article

Comorbidities according to airflow limitation severity: data from comprehensive health examination in Japan

Authors: Shota Masuda, Hisamitsu Omori, Ayumi Onoue, Xi Lu, Kenichi Kubota, Noritaka Higashi, Yasuhiro Ogata, Takahiko Katoh

Published in: Environmental Health and Preventive Medicine | Issue 1/2017

Login to get access

Abstract

Objectives

The present study aimed to investigate the relationship between airflow limitation (AL) severity and comorbidities in comprehensive health examination.

Methods

This cross-sectional study included 6661 men and 6044 women aged 40–89 who underwent a lung function test during medical checkups. AL was defined as forced expiratory volume in 1 s/forced vital capacity of < 0.7. Logistic regression analysis was used to assess the association between AL severity and the presence of comorbidities.

Results

When compared with the normal lung function group, subjects with AL had a higher prevalence of lung cancer (odd ratio (OR) 9.88, 95% confidence interval (CI) 3.88–25.14) in men, hypertension (OR 1.63, 95% CI 1.26–2.10) in women, diabetes and hyperglycemia (OR 1.23, 95% CI 1.02–1.49 in men, OR 1.61, 95% CI 1.18–2.20 in women) in men and women after adjusting for potential confounders. In men, lung cancer and MetS (the Joint Interim Statement: JIS) were significantly associated with moderate-to-very severe AL after adjustment. In women, hypertension, diabetes and hyperglycemia, MetS (JIS), and MetS (the Japanese Committee of the Criteria for MetS: JCCMS) were significantly associated with mild AL after adjustment. Hypertension was significantly associated with moderate-to-very severe AL after adjustment in women.

Conclusions

Significant relationships were found between AL severity and the presence of comorbid lung cancer in men, hypertension in women, diabetes and hyperglycemia, and MetS in men and women. Knowledge of comorbidities associated with AL should be widely publicized to raise the awareness of chronic obstructive pulmonary disease (COPD).
Literature
1.
go back to reference Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, Updated 2015. http://goldcopd.org/. Accessed 8 Aug 2016. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, Updated 2015. http://​goldcopd.​org/​. Accessed 8 Aug 2016.
2.
go back to reference Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.CrossRefPubMed Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.CrossRefPubMed
4.
go back to reference Divo M, Cote C, de Torres JP, Casanova C, Martin JM, Pinto-Plata V, BODE Collaborative Group, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:155–61.CrossRefPubMed Divo M, Cote C, de Torres JP, Casanova C, Martin JM, Pinto-Plata V, BODE Collaborative Group, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:155–61.CrossRefPubMed
5.
go back to reference Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962–9.CrossRefPubMed Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962–9.CrossRefPubMed
6.
go back to reference Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006;28:1245–57.CrossRefPubMed Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006;28:1245–57.CrossRefPubMed
7.
go back to reference Gershon AS, Mecredy GC, Guan J, Victor JC, Goldstein R, To T. Quantifying comorbidity in individuals with COPD: a population study. Eur Respir J. 2015;45:14–7.CrossRef Gershon AS, Mecredy GC, Guan J, Victor JC, Goldstein R, To T. Quantifying comorbidity in individuals with COPD: a population study. Eur Respir J. 2015;45:14–7.CrossRef
8.
go back to reference Oda M, Omori H, Onoue A, Cui X, Lu X, Yada H, et al. Association between airflow limitation severity and arterial stiffness as determined by the brachial-ankle pulse wave velocity: A cross-sectional study. Intern Med. 2015;54(20):2569–75.CrossRefPubMed Oda M, Omori H, Onoue A, Cui X, Lu X, Yada H, et al. Association between airflow limitation severity and arterial stiffness as determined by the brachial-ankle pulse wave velocity: A cross-sectional study. Intern Med. 2015;54(20):2569–75.CrossRefPubMed
9.
go back to reference Onoue A, Omori H, Katoh T, Kubota K, Nonami Y, Ogata Y, et al. Relationship of airflow limitation severity with work productivity reduction and sick leave in a Japanese working population. Int J Chron Obstruct Pulmon Dis. 2016;11:567–75.PubMedPubMedCentral Onoue A, Omori H, Katoh T, Kubota K, Nonami Y, Ogata Y, et al. Relationship of airflow limitation severity with work productivity reduction and sick leave in a Japanese working population. Int J Chron Obstruct Pulmon Dis. 2016;11:567–75.PubMedPubMedCentral
10.
go back to reference Omori H, Tsuji M, Sata K, Iyonaga C, Narimatsu A, Mihara S, et al. Correlation of C-reactive protein with disease severity in CT diagnosed emphysema. Respirology. 2009;14:551–8.CrossRefPubMed Omori H, Tsuji M, Sata K, Iyonaga C, Narimatsu A, Mihara S, et al. Correlation of C-reactive protein with disease severity in CT diagnosed emphysema. Respirology. 2009;14:551–8.CrossRefPubMed
11.
go back to reference Funakoshi Y, Omori H, Mihara S, Marubayashi T, Katoh T. Association between Airflow Obstruction and the Metabolic Syndrome or Its Components in Japanese Men. Intern Med. 2010;49(19):2093–9.CrossRefPubMed Funakoshi Y, Omori H, Mihara S, Marubayashi T, Katoh T. Association between Airflow Obstruction and the Metabolic Syndrome or Its Components in Japanese Men. Intern Med. 2010;49(19):2093–9.CrossRefPubMed
12.
go back to reference Omori H, Nagano M, Funakoshi Y, Onoue A, Mihara S, Marubayashi T, et al. Twelve-year cumulative incidence of airflow obstruction among Japanese males. Intern Med. 2011;50(15):1537–44.CrossRefPubMed Omori H, Nagano M, Funakoshi Y, Onoue A, Mihara S, Marubayashi T, et al. Twelve-year cumulative incidence of airflow obstruction among Japanese males. Intern Med. 2011;50(15):1537–44.CrossRefPubMed
13.
go back to reference Funakoshi Y, Omori H, Mihara S, Onoue A, Ogata Y, Aizawa H, et al. C-reactive protein levels, airflow obstruction, and chronic kidney disease. Environ Health Prev Med. 2012;17(1):18–26.CrossRefPubMed Funakoshi Y, Omori H, Mihara S, Onoue A, Ogata Y, Aizawa H, et al. C-reactive protein levels, airflow obstruction, and chronic kidney disease. Environ Health Prev Med. 2012;17(1):18–26.CrossRefPubMed
14.
go back to reference Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRefPubMed Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRefPubMed
16.
go back to reference Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Athrosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.CrossRefPubMed Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Athrosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.CrossRefPubMed
17.
go back to reference Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Definition and diagnostic criteria for metabolic syndrome. Nippon Naika Gakkai Zasshi. 2005;94:794-809. (in Japanese) Committee to Evaluate Diagnostic Standards for Metabolic Syndrome. Definition and diagnostic criteria for metabolic syndrome. Nippon Naika Gakkai Zasshi. 2005;94:794-809. (in Japanese)
18.
go back to reference Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. Arch Intern Med. 2003;163(12):1475–80.CrossRefPubMed Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. Arch Intern Med. 2003;163(12):1475–80.CrossRefPubMed
19.
go back to reference de Torres JP, Marin JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung cancer in patients with chronic obstructive pulmonary disease: incidence and predicting factors. Am J Respir Crit Care Med. 2011;184:913–9.CrossRefPubMed de Torres JP, Marin JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung cancer in patients with chronic obstructive pulmonary disease: incidence and predicting factors. Am J Respir Crit Care Med. 2011;184:913–9.CrossRefPubMed
20.
go back to reference Kiri VA, Soriano J, Visick G, Fabbri L. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J. 2010;19(1):57–61.CrossRefPubMed Kiri VA, Soriano J, Visick G, Fabbri L. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J. 2010;19(1):57–61.CrossRefPubMed
21.
go back to reference Rabe KF, Wedzicha JA, Wouters EFM, editors. COPD and comorbidity, European Respiratory Monograph. 2013. p. 59. Rabe KF, Wedzicha JA, Wouters EFM, editors. COPD and comorbidity, European Respiratory Monograph. 2013. p. 59.
22.
go back to reference Loganathan RS, Stover DE, Shi W, Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest. 2006;129:1305–12.CrossRefPubMed Loganathan RS, Stover DE, Shi W, Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest. 2006;129:1305–12.CrossRefPubMed
23.
go back to reference Patel ARC, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med. 2011;5(5):647–62.CrossRefPubMed Patel ARC, Hurst JR. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med. 2011;5(5):647–62.CrossRefPubMed
24.
go back to reference Hu H, Kurotani K, Sasaki N, Murakami T, Shimizu C, Shimizu M, et al. Optimal waist circumference cut-off points and ability of different metabolic syndrome criteria for predicting diabetes in Japanese men and women: Japan Epidemiology Collaboration on Occupational Health Study. BMC Public Health. 2016;16:220–9.CrossRefPubMedPubMedCentral Hu H, Kurotani K, Sasaki N, Murakami T, Shimizu C, Shimizu M, et al. Optimal waist circumference cut-off points and ability of different metabolic syndrome criteria for predicting diabetes in Japanese men and women: Japan Epidemiology Collaboration on Occupational Health Study. BMC Public Health. 2016;16:220–9.CrossRefPubMedPubMedCentral
25.
go back to reference Takahashi S, Betsuyaku T. The chronic obstructive pulmonary disease comorbidity spectrum in Japan differs from that in western countries. Respir Investig. 2015;53:259–70.CrossRefPubMed Takahashi S, Betsuyaku T. The chronic obstructive pulmonary disease comorbidity spectrum in Japan differs from that in western countries. Respir Investig. 2015;53:259–70.CrossRefPubMed
26.
go back to reference Diez-Manglano J, Barquero-Romero J, Almagro P, Cabrera FJ, Lopez Garcia F, Montero L, Working Group on COPD; Spanish Society of Internal Medicine, et al. COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med. 2014;9:419–25.CrossRefPubMed Diez-Manglano J, Barquero-Romero J, Almagro P, Cabrera FJ, Lopez Garcia F, Montero L, Working Group on COPD; Spanish Society of Internal Medicine, et al. COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med. 2014;9:419–25.CrossRefPubMed
27.
go back to reference Watz H, Waschki B, Kirsten A, Muller KC, Kretschmar G, Meyer T, et al. The metabolic syndrome in patients with chronic bronchitis and COPD. Frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009;136:1039–46.CrossRefPubMed Watz H, Waschki B, Kirsten A, Muller KC, Kretschmar G, Meyer T, et al. The metabolic syndrome in patients with chronic bronchitis and COPD. Frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009;136:1039–46.CrossRefPubMed
28.
go back to reference Basili S, Ferroni P, Vieri M, Cardelli P, Ceci F, Paradiso M, et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis. 1999;147:249–52.CrossRefPubMed Basili S, Ferroni P, Vieri M, Cardelli P, Ceci F, Paradiso M, et al. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis. 1999;147:249–52.CrossRefPubMed
29.
30.
go back to reference Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204–12.CrossRefPubMed Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204–12.CrossRefPubMed
31.
go back to reference Price D, Freeman D, Cleland J, Kaplan A, Cerasoli F. Earlier diagnosis and earlier treatment of COPD in primary care. Prim Care Respir J. 2011;20:15–22.CrossRefPubMed Price D, Freeman D, Cleland J, Kaplan A, Cerasoli F. Earlier diagnosis and earlier treatment of COPD in primary care. Prim Care Respir J. 2011;20:15–22.CrossRefPubMed
32.
go back to reference Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765–73.CrossRefPubMed Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765–73.CrossRefPubMed
Metadata
Title
Comorbidities according to airflow limitation severity: data from comprehensive health examination in Japan
Authors
Shota Masuda
Hisamitsu Omori
Ayumi Onoue
Xi Lu
Kenichi Kubota
Noritaka Higashi
Yasuhiro Ogata
Takahiko Katoh
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Environmental Health and Preventive Medicine / Issue 1/2017
Print ISSN: 1342-078X
Electronic ISSN: 1347-4715
DOI
https://doi.org/10.1186/s12199-017-0620-0

Other articles of this Issue 1/2017

Environmental Health and Preventive Medicine 1/2017 Go to the issue